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ABSTRACT
Thirty patients with early onset breast cancer
or familial breast cancer from Malaysia were
analysed for germline mutation in the early onset
breast cancer 1 gene (BRCA1). Direct sequencing
of the entire coding region of BRCA1 identified
a frameshift mutation, c.5447-5448insC (insC5447)
(codon 1776 of exon 21) in a patient aged 32
of the Malay ethnic origin, who had no family
history of breast and/or ovarian cancer. Eight
polymorphisms (2201C>T, 2430T>C, P871L,
E1038G, K1183R, 4427T>C, S1613G and IVS8-
57delT) were identified in the samples tested.
Keywords: BRCA1, Breast cancer, Ethnic, Mutation,
Malaysian
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INTRODUCTION
Breast cancer is a common malignancy affecting
women around the world, including Malaysia.
In 1995, 9.6% of the admissions for cancer in the
government hospitals in Malaysia was for breast
cancer(1) and 20% of 317 women who died of breast
cancer were below the age of 40(2). Early onset
breast cancer susceptibility gene (BRCA1) has been
linked to 52% of families with breast cancer(3,4).
Germline mutations of BRCA1 in families are estimated
to increase the risk of developing breast cancer for the
first time for BRCA1 carriers at 73% by the age of
50 and 87% by 70 years(4). There is also a 29% risk
for breast cancer patients to develop ovarian cancer
by 50 years and 44% by 70 years(4).
Germline BRCA1 mutations have been identified
in young-onset breast cancer patients without a strong
family history of breast cancer. Greenman et al(5)
reported BRCA1 mutations in 18% patients (five out
of 27) with families with one to three relatives with
breast or ovarian cancer. Another study identified
15 mutations from 208 breast cancer patients below
the age of 45 who had first degree breast cancer
family history (affected mother and/or sister with
breast cancer)(6). These studies show that a large
proportion of women with first degree breast cancer
family history may not carry germline mutations.
However, in studies with four or more first degree
relatives with breast and/or ovarian cancer, a higher
prevalence of mutations have been reported. Couch
et al(7) identified that 45% of families carried BRCA1
mutations and similar findings were reported in
30 Canadian families(8).
Other breast cancer predisposing genes associated
with familial breast cancer are the breast cancer 2
gene (BRCA2) and Phosphatase and Tensin Homolog
(PTEN). BRCA2 was found to be linked to 32% in
families with breast cancer. However, the risk of
developing breast cancer associated with BRCA2
is lower compared to BRCA1(4). In addition, BRCA2
mutations among male carriers confer a higher risk
of male breast cancer compared to BRCA1(4). PTEN
mutations have been associated with Cowden
syndrome, characterised by multiple hamartomatous
lesions of the skin, mucous membranes, intestinal
polyps and increased risk of breast and thyroid
cancer. Although PTEN mutations have been found in
sporadic and familial breast cancer cases, it is not a
major determinant of non-BRCA1/BRCA2 cases(9,10).
Currently, most reported BRCA1 mutations are
from those of Caucasian origin and the type of
mutations in Asians could be different. Li et al(11)
screened for BRCA1 mutations using single strand
conformational polymorphism (SSCP) in patients
with familial breast cancer and identified a novel
mutation. BRCA1 mutation analysis in tumours of
sporadic breast cancer cases unselected for age and
early onset breast cancer cases in Chinese from
Hong Kong identified 589delCT as a potential
candidate founder BRCA1 mutation among the
Chinese(12). In Singapore, the study of 43 breast cancer
patients found 2846insA in two unrelated Malay
families(13). Japanese studies found BRCA1 mutations
to be unique to the country(14,15). These reports also
observed that the prevalence of BRCA1 mutations
among their patients was similar to those reported in
United States. SSCP was used in all the studies
reported above.
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Malaysia is a country in South East Asia with
the main ethnic groups being the Malays, Chinese and
Indians. Information on BRCA1 mutations in the
Malay ethnic group, a major ethnic group in South
East Asia is still lacking. In this study, we carried a
detailed analysis of the BRCA1 gene in patients in
Malaysia regardless of their ethnicity. The entire
coding region of BRCA1 gene was analysed by direct
sequencing, as this approach would cause the least bias
in the type of mutation identified while theoretically
being the most sensitive method. This is important as
the information on the mutation spectra of BRCA1
among breast cancer patients (particularly among
those with early onset sporadic breast cancer) in this
region is limited. We performed the comprehensive
screening for BRCA1 mutations in Malaysian patients
with early onset breast cancer and those with two or
more relatives with breast and/or ovarian cancers.
MATERIALS AND METHODS
We screened BRCA1 mutations in two clinically
selected groups for whom testing might be indicated.
The first group comprised of histologically confirmed
cases of breast cancer aged below 35 years (i.e. early
onset) and the second group comprised of histologically
confirmed cases of breast cancer with two or more first
or second degree relatives with breast and/or ovarian
cancers regardless of age (i.e. familial breast cancer).
The family histories of these women are summarised
in Table I.
Breast cancer patients from the three main ethnic
groups seen in Kuala Lumpur Hospital between
1994 and 1998 in average were 45% Malays, 35%
Chinese and 18% Indians. Individuals from the
different ethnic groups in Malaysia were represented
in our series of patients - i.e. 16 (53%) Malays, 9 (30%)
Chinese and 5 (17%) Indian.
Patients identified were attending the Breast Clinic,
Kuala Lumpur Hospital, Malaysia from 1994 to 1998
and blood was collected from consenting individuals.
Polymerase chain reaction was carried out with
primers(16,17) on leukocyte DNA for the entire coding
region of the BRCA1 gene in 37 separate reactions,
followed by direct sequencing with the ABI PRISMTM
dRhodamine Terminator Cycle Sequencing Ready
Reaction Kit on ABI PRISMTM 310 Genetic Analyser.
Sequences obtained were compared with the published
sequence (GenBank Acc. No. L78833).
RESULTS
Between 1994 and 1996 approximately 10% of the
patients diagnosed at the Kuala Lumpur Breast Clinic
were at or below the age of 35 while 2 - 5% of patients
had two or more relatives with breast and/or ovarian
cancer. Among the patients aged 35 years or below,
none of them had any family history of cancer and
only two of the patients had bilateral breast cancer.
Patients studied comprised of 23 patients who were
aged 35 or below of which two of them had a family
history of breast cancer, and seven patients aged
between 40 to 70 with a history of breast and/or
ovarian cancer. An insertion was found in exon 21
in nucleotide 5447 codon 1776 in a 32-year-old patient
of the Malay origin (Fig. 1). This mutation is predicted
to result in a premature stop codon at position 1829.
The eight polymorphisms identified and the number
of cases in which they were identified are listed in
Table II. All polymorphisms identified in patients
were from the three ethnic groups studied in exception
of one.
DISCUSSION
In our study, 4.3% (1/23) of our breast cancer patients
aged 35 years or below had BRCA1 mutations. The
detection of one frameshift mutation in this group
Table I. Age and family history of patients.
Patient no. Age (years) Family history
1 40 Mother, sister and maternal aunt (breast cancer)
2 55 Sister and 3 maternal aunts (breast cancer);
Father (stomach cancer)
3 57 2 sisters (breast cancer)
4 25 Paternal grandmother and 1 maternal aunt
(breast cancer);
1 maternal aunt (ovarian cancer)
5 70 2 maternal aunt (breast cancer)
6 45 Mother (breast cancer);
Sister (ovarian cancer)
7 50 2 sisters (breast cancer)
8 49 2 maternal aunts and 1 maternal aunt’s daughter
(breast cancer)
Fig. 1 Electropherogram of the frameshift mutation, c.5447-
5448insC of exon 21. The mutant sequence (mut) with the insertion
of C underlined and the wild type sequence (wt) are shown.
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could explain the moderate role of BRCA1 in the
pathogenesis of breast cancer in this age group.
BRCA1 mutational studies conducted among
Caucasian patients from the same age group and
without family history as in this study identified
BRCA1 mutations in 6 (5.7%) of the 105 patients(18)
and 12 (6.2%) of the 193 patients(6). These are quite
similar as seen in our study.
The frameshift mutation, c.5447-5448insC
(insC5447) (codon 1776 of exon 21) was found in a
patient aged 32 with non-cancer family history. The
patient had a grade 3 cancer with negative oestrogen
receptor. Johnasson et al(19) found BRCA1 related
tumours to be oestrogen receptor negative. Another
study which analysed tumours of patients aged
below 40 years observed that younger patients are
linked with adverse pathological features such as
grade 3 tumour, oestrogen receptor negative and
lymphatic vessel involvement(20). In our patient there
were histologically positive nodes. The same mutation
identified in our patient had been identified in a
Dutch Caucasian study among familial breast cancer
patients(21). This truncating mutation would disrupt the
involvement of BRCA1 in DNA binding and in
protein-protein interactions(22).
Ethnicity differences and the small sample size
among our patients may contribute to the low number
of mutations identified in the study. The potential
founder mutation, 589delCT reported among Chinese
was not found in our series of nine Chinese patients(12).
In the Malay ethnic group, we studied 16 patients but
did not find the 2846insA and 2885delA mutations
found among Malay patients in Singapore(13).
Studies have shown that BRCA1 mutations are
not common among breast cancer patients with a
modest history of breast cancer. A study of 169 cases
of women with a history of one to 11 cases of breast
cancer per family only reported 27 BRCA1 mutations(7).
Malone et al(6) found BRCA1 mutations in 1.2% of
patients (14 out of 312) with families having fewer
than four cases of breast cancer only, with no history
of ovarian cancer. In our study, it is possible that breast
cancer among the four patients with at least three
relatives was not due to BRCA1 mutations. The lack
of BRCA1 mutations among the breast cancer
patients with family history also may be due to
mutations in the noncoding regions of BRCA1 and
the existence of other breast cancer susceptibility
genes such as BRCA2 and PTEN. The presence of
mutations in the intron and noncoding regions of
the gene would affect RNA transcription, splicing and
stability. Swensen et al(23) identified a 14kb deletion
that removed both of the BRCA1 transcription start
sites. In addition, mutational analysis using direct
sequencing could miss large deletions. Puget et al(24)
identified large germline rearrangements among
American and French breast cancer families that
did not indicate BRCA1 mutation using classical
detection techniques.
Polymorphisms previously found in Caucasians(16,25)
and also identified in Chinese(12): 2201C>T, 2430T>C,
2731C>T, 3232A>G, 4227T>C and 4956A>G were
found in our series of patients. The IVS8-57delT
polymorphism found in Hispanics was detected in
the three ethnic groups among our patients(26). Our
finding of at least one heterozygous polymorphism in
20 of our 30 patients indicate that the deletion of the
entire BRCA1 gene did not occur in these patients.
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